This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Humanigen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Humanigen yıllık ortalama 72.1% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.1% annual. Gelirler azalıyor .

Anahtar bilgiler

72.1%

Kazanç büyüme oranı

83.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-59.0%
Özkaynak getirisi	n/a
Net Marj	-3,156.8%
Son Kazanç Güncellemesi	31 Mar 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

Gelir ve Gider Dağılımı

Humanigen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:HGEN.Q Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 23	2	-54	15	0
31 Dec 22	3	-71	16	0
30 Sep 22	3	-109	16	26
30 Jun 22	4	-152	19	-97
31 Mar 22	4	-192	23	-60
31 Dec 21	4	-237	23	0
30 Sep 21	3	-235	23	0
30 Jun 21	2	-199	25	123
31 Mar 21	1	-153	19	59
31 Dec 20	0	-90	16	0
30 Sep 20	0	-59	13	0
30 Jun 20	0	-31	6	1
31 Mar 20	0	-10	6	3
31 Dec 19	0	-10	6	3
30 Sep 19	0	-10	6	3
30 Jun 19	0	-10	7	3
31 Mar 19	0	-9	7	2
31 Dec 18	0	-12	9	2
30 Sep 18	0	-13	10	3
30 Jun 18	0	-18	10	6
31 Mar 18	0	-22	9	9
31 Dec 17	0	-22	8	11
30 Sep 17	0	-24	7	13
30 Jun 17	0	-21	8	11
31 Mar 17	0	-27	9	11
31 Dec 16	0	-27	8	10
30 Sep 16	0	-35	11	11
30 Jun 16	0	-37	11	13
31 Mar 16	0	-31	11	12
31 Dec 15	0	-35	13	15
30 Sep 15	0	-32	10	19
30 Jun 15	0	-33	10	20
31 Mar 15	0	-37	11	24
31 Dec 14	0	-38	10	27
30 Sep 14	0	-39	10	19
30 Jun 14	0	-42	10	14
31 Mar 14	0	-44	9	8
31 Dec 13	0	-42	8	0
30 Sep 13	0	-43	8	0

Kaliteli Kazançlar: HGEN.Q şu anda kârlı değil.

Büyüyen Kar Marjı: HGEN.Q şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: HGEN.Q 'un son 5 yılda yıllık kazanç büyüme oranının pozitif olup olmadığını belirlemek için yeterli veri yok.

Büyüme Hızlandırma: HGEN.Q 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: HGEN.Q kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: HGEN.Q 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

This company is no longer active

Humanigen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2023 earnings released: US$0.035 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

First half 2022 earnings released

Recent updates

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Humanigen, Inc. Announces Board Changes

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.035 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.75

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Humanigen Receives Non-Compliance Letter from Nasdaq

Bernstein Liebhard LLP Announces Class Action Lawsuit Against Humanigen, Inc

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022

Pomerantz LLP Announces the Filing of a Class Action Against Humanigen, Inc. and Certain of its Officers

Consensus revenue estimates increase by 34%

First half 2022 earnings released

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Price target decreased to US$8.70

Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

Humanigen plunges 57% as trial for COVID-19 therapy fails

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Consensus revenue estimates increase by 19%

Humanigen, Inc., Annual General Meeting, Jun 09, 2022

Chairman & CEO recently bought US$94k worth of stock

Forecast to breakeven in 2023

Consensus revenue estimates increase by 12%

Forecast to breakeven in 2023

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Humanigen, Inc. Announces Target Enrollment in Phase 2/3 Activ-5/Bet-B Trial of Lenzilumab for the Treatment of Covid-19 Has Been Achieved

Humanigen, Inc. Announces A Manuscript Detailing the Results of an Analysis of CRP Levels from the Live-Air Phase 3 Study

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

FDA Declines Humanigen’s Emergency Use Authorization Request for Lenzilumab in Hospitalized COVID-19 Patients

Price target decreased to US$28.33

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Chairman & CEO recently sold US$1.7m worth of stock

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Humanigen Submits Application to FDA for Emergency Use Authorization for lenzilumab in Covid-19

Humanigen submits lenzilumab COVID-19 EUA application to FDA

Eversana Advances Commercialization Readiness as Humanigen Announces Publication of Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Newly Hospitalized Covid-19 Patients

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Price target increased to US$32.14

Humanigen, Inc., Annual General Meeting, Jun 17, 2021

Humanigen, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Earnings beat expectations

Chief Accounting & Administrative Officer, Corporate Secretary and Treasurer has left the company

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

New 90-day high: US$23.83

Humanigen, Inc. Announces Executive Changes

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

Humanigen, Inc. Completes Enrollment in Phase 3 Study of Lenzilumab

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational Covid-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

Humanigen, Inc Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19

Humanigen, Inc. and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Humanigen, Inc. Announces Retirement of Robert G. Savage from the Board of Directors

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme

New 90-day high: US$15.51